Efficacy and Safety of Ultratrace™ Iobenguane I 131 in Neuroblastoma
NCT ID: NCT00992173
Last Updated: 2015-11-26
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
WITHDRAWN
PHASE2
INTERVENTIONAL
2010-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
In this study the investigators are investigating the use of a new form of Iobenguane I 131 called Ultratrace iobenguane I 131. This form is expected to deliver higher amounts of radioactive I 131 to the neuroblastoma cells. The primary purpose of the study is to determine if Ultratrace iobenguane I 131 can be used to successfully treat high-risk neuroblastoma. The study will also assess the safety of Ultratrace iobenguane I 131 when given to patients with high-risk neuroblastoma.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Ultratrace Iobenguane I 131
Ultratrace Iobenguane I 131
Subjects will receive an Imaging Dose of 0.1 mCi/kg \[3.7 MBq/kg\] (a minimum dose of 1.0 mCi \[37 MBq\] but not to exceed 5.0 mCi \[185 MBq\]) of Ultratrace iobenguane I 131 to have dosimetry performed and to confirm tumor uptake of the test article prior to receiving each of 2 planned Therapeutic Doses of Ultratrace iobeneguane I 131 . Within 28 days of screening, eligible subjects (as confirmed by the first Imaging dose study)will receive an Ultratrace iobenguane I 131 Therapeutic dose of of 15.0 - 18.0 mCi/kg (max. 666 MBq/kg) followed by imaging 7 days later or upon discharge from radiation isolation. A second Therapeutic Dose (preceded by a repeat Image Dose and dosimetry study)and imaging upon discharge from radiation isolation will be repeated approximately 8 weeks after the first dose.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Ultratrace Iobenguane I 131
Subjects will receive an Imaging Dose of 0.1 mCi/kg \[3.7 MBq/kg\] (a minimum dose of 1.0 mCi \[37 MBq\] but not to exceed 5.0 mCi \[185 MBq\]) of Ultratrace iobenguane I 131 to have dosimetry performed and to confirm tumor uptake of the test article prior to receiving each of 2 planned Therapeutic Doses of Ultratrace iobeneguane I 131 . Within 28 days of screening, eligible subjects (as confirmed by the first Imaging dose study)will receive an Ultratrace iobenguane I 131 Therapeutic dose of of 15.0 - 18.0 mCi/kg (max. 666 MBq/kg) followed by imaging 7 days later or upon discharge from radiation isolation. A second Therapeutic Dose (preceded by a repeat Image Dose and dosimetry study)and imaging upon discharge from radiation isolation will be repeated approximately 8 weeks after the first dose.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Have a diagnosis of neuroblastoma either by (a) histologic verification of neuroblastoma and/or (b) demonstration of tumor cells in the bone marrow with increased urinary catecholamine metabolites
3. Have high-risk neuroblastoma with relapsed/refractory disease at any time.
4. MIBG avid disease demonstrated by 131I or 123I -MIBG uptake into tumor at ≥ one site within 28 days prior to study treatment and no intervention/therapy between the time of the MIBG scan and study treatment.
5. To be eligible to receive at least one therapeutic dose, patients must have adequate banked autologous stem cells defined as:
PBSC: A minimum of 2.0 x 106 viable CD34+ cells/kg (purged or unpurged) (see Section 10.4.15)
6. Prior Therapy:
1. Patients must have fully recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy prior to entering this study. There is no limitation on the number of prior chemotherapeutic regimens that the patient may have received.
2. The last dose of all local palliative radiation must be ≥ 14 days prior to the first therapeutic dose of Ultratrace iobenguane I 131. Any lesion treated with local palliative radiation during this period can not be included in the baseline target lesion evaluation.
3. The last dose of all local palliative radiation to more than 25% of marrow containing bones must be ≥ 28 days prior to the first therapeutic dose of Ultratrace iobenguane I 131. A minimum of 3 months is required following prior large field radiation therapy (i.e. craniospinal therapy, total lung, \> 50% marrow space). Note: Radiation therapy of focal skull-based bony metastatic disease (only) is not considered craniospinal therapy.
4. The last dose of any myelosuppressive or biologic (e.g., isotretinoin \[also known as cis-retinoic acid, or Accutane®\]) therapy must be at least 14 days before the administration of the first therapeutic dose of Ultratrace iobenguane I 131 on this protocol.
5. The last dose of immunotherapy must be at least 28 days prior to the first therapeutic dose of Ultratrace iobenguane I 131.
6. All cytokines or hematopoietic growth factors must be discontinued for a minimum of 7 days prior to the first therapeutic dose of Ultratrace iobenguane I 131or 14 days prior to the first therapeutic dose of Ultratrace iobenguane I 131for long-acting colony stimulating factors.
7. Prior treatment with 131I-MIBG therapy must be ≥12 months prior to the first therapeutic dose of Ultratrace iobenguane I 131.
8. Administration of Neuroblastoma therapeutic investigational medication or devices must be ≥30 days prior to dosimetry dose.
9. Prior autologous stem cell infusion must be ≥2 months prior to study entry. The patient must have recovered from all toxicities
7. Adequate Organ Function:
1. Adequate bone marrow function requirements, including patients post-myeloablative therapy or tumor involvement of bone marrow
2. Adequate renal, hepatic, cardiac, lung and thyroid function
Exclusion Criteria
1. Pregnant, or lactating females with the intent to breast feed. Females of child-bearing potential must have a negative serum pregnancy test prior to therapy. Males and females of reproductive age and childbearing potential must use effective contraception defined as abstinence or use of IUD, oral contraceptive, barrier and spermicide, or hormonal implant for the duration of their participation. Sexually active female patients using oral contraception will be required to use a second form of barrier birth control. All patients will be required to use effective contraception for 60 days following the last therapeutic dose of Ultratrace iobenguane I 131.
2. Have disease of any major organ system that would compromise their ability to withstand therapy.
3. Receiving hemodialysis or have a renal obstruction, which would effect the urinary excretion of MIBG.
4. Is platelet transfusion dependent
5. Status post-allogeneic hematopoietic stem cell transplant.
6. Concomitant use of medications that inhibit uptake of Ultratrace iobenguane I 131.
7. Have a known allergy to iobenguane, iodine or SSKI.
8. If patients and/or families who are physically and psychologically unable to cooperate with the radiation safety isolation or imaging requirements (sedation or general anesthesia permitted).
9. Administered prior chemotherapy within 30 days of study entry or have active malignancy (other than neuroblastoma) requiring additional treatment.
10. Any other condition, that in the opinion of the investigator, may compromise the safety or compliance of the subject or would preclude the subject from successful completion of the study.
11. Patient unable to receive at least one 15 mCi/kg dose per dosimetry findings.
12 Months
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Molecular Insight Pharmaceuticals, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Norman LaFrance, MD
Role: STUDY_DIRECTOR
Molecular Insight Pharmaceutical Employee
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Children's Hospital of LA
Los Angeles, California, United States
UCSF Pediatric Hematology/Oncology
San Francisco, California, United States
University of Miami Miller School of Medicine
Miami, Florida, United States
Childrens Memorial/Northwestern University
Chicago, Illinois, United States
Comer's Childrens Hospital/University of Chicago
Chicago, Illinois, United States
University of iowa
Iowa City, Iowa, United States
Johns Hopkins University
Baltimore, Maryland, United States
Children's Hospital/Dana Farber Cancer Institute
Boston, Massachusetts, United States
CS Motts Children's Hospital
Ann Arbor, Michigan, United States
Mount Sinai School of Medicine
New York, New York, United States
Hospital - Weill Cornell Medical Center
New York, New York, United States
Memorial Sloan Kettering
New York, New York, United States
Duke University Medical Center
Durham, North Carolina, United States
Cincinnati Children's Hospital
Cincinnati, Ohio, United States
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania, United States
Medical University of South Carolina
Charleston, South Carolina, United States
Cook Children's Healthcare System
Fort Worth, Texas, United States
MD Anderson Cancer Center
Houston, Texas, United States
Texas Childrens Hospital Cancer Center
Houston, Texas, United States
University of Wisconsin Medical Center
Madison, Wisconsin, United States
The Hospital for Sick Children
Toronto, Ontario, Canada
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MIP-IB-N201
Identifier Type: -
Identifier Source: org_study_id